Trial Profile
A Phase 1, Open-label, Randomised, Cross Over Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects Following Single Doses
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs FDL 169 (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Flatley Discovery Lab
- 01 Nov 2018 Status changed from recruiting to completed.
- 18 May 2018 New trial record